Valproate pregnancy prevention — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Escalate to the prescriber before supply unless the required pregnancy-prevention safeguards are confirmed.
Valproate has major teratogenic and neurodevelopmental risks and is subject to strict pregnancy-prevention requirements in people who could become pregnant. If safeguards are not confirmed, the pharmacist should escalate to the prescriber urgently and manage supply in a way that avoids abrupt withdrawal risk. The pharmacist cannot independently switch antiepileptic therapy.
Reference: MHRA Drug Safety Update; BNF